Lansoprazole 103577-45-3

Pharmacology

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available. Lansoprazole is a racemate [1:1-mixture of the enantiomers dexlansoprazole (Kapidex) and levolansoprazole]. Dexlanprantazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'. Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i. e. gastric acid suppression). The mean plasma elimination half-life is 1. 5 hours, and the effects of the drug last for over 24 hours after it has been used for 1 day or more. Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i. v. pantoprazole in patients who are unable to swallow solid dosage formulations.

Indications

Lansoprazole is indicated for:*Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers*Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)*Treatment of Zollinger-Ellison Syndrome*Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics

Drug interactions

• PPIs reduce absorption of antifungals and possibly increase Digoxin in plasma
• Increases plasma concentrations of Cilostazol (risk of toxicity)
• Absorption of lansoprazole possibly reduced by:
  • sucralfate
  • ampicillin
  • bisacodyl
  • delavirdine
  • fluvoxamine
  • iron salts
  • theophylline
  • voriconazole
  • aminophylline and theophylline
  • astemizole

Side effects

• Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
• Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions including
• Severe: Gastro-intestinal disturbances (such as nausea 1. 3%, abdominal pain 2. 1%, diarrhea 3. 8%). Proton-pump inhibitors may be associated with a greater risk of hip fractures, Clostridium difficile-associated diarrhea. Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.

Brand names

The drug is sold under several brand names, including:

• Agopton (Germany)
• Digest (Indonesia)
• Duogast (Syria)
• Gastrolan (Indonesia)
• Lanciprol (Greece)
• Lansazol (Jordan)
• Lansobene (Austria)
• Lansoloc (South Africa)
• Lansoprazol (Denmark)
• Lansoptol (Hungary)
• Lansor (Turkey)
• Lansox (Italy)
• Lanston LFDT (South Korea)
• Lenzo (India)
• Lanzol (India)
• Lanzotec (Jordan)
• Lanzul (Slovenia)
• Lanton (Israel)
• Lanzo (Sweden)
• Lanzor (France, South Africa)
• Lanzostad (Lithuania, Latvia, Estonia)
• Laprazol (Greece)
• Limpidex (Italy)
• Monolitum (Spain)
• Ogast and OgastORO (France)
• Ogastro (Mexico)
• Prevacid (U.S. and Canada) Prevacid is a product of Takeda Pharmaceuticals.
• Prevacid 24HR (U.S.)
• Prosogan and Prosogan FD (Indonesia)
• pro-ulco (Spain)
• Refluxon (Hungary)
• SOLOX (New Zealand)
• Takepron (Japan)
• Zolt (Finland)
• Zoton (Italy, Ireland, Australia, UK)
• ZOMEL (Ireland)